Neuralia TMS Delivers Advanced TMS Therapy for OCD Treatment
Australia, 17th Mar 2026 – Neuralia TMS, a leader in non-invasive neurological treatments, has announced an expansion of its services to include transcranial Direct Current Stimulation (tDCS), an at-home neuromodulation therapy, as well as pharmacogenetic testing to optimise treatment outcomes. Known for its expertise in Transcranial Magnetic Stimulation (TMS) therapy, Neuralia TMS continues to provide evidence-based, drug-free treatments for individuals experiencing conditions such as depression, anxiety, PTSD, obsessive-compulsive disorder (OCD), chronic pain, and Parkinson’s disease.
Dr Shanek Wick, Medical Director at Neuralia TMS, provided insight into the company’s latest offerings: “The integration of transcranial Direct Current Stimulation (tDCS) into the treatment portfolio refle...
